Urology Care

The American Society of Clinical Oncology recently reported favorable results of a Phase 2 therapeutic trial of a vaccine called Prostvac-VF in the treatment of men with metastatic hormone-refractory prostate cancer.  Men who received the vaccine had a median overall survival that was 8.5 months longer than the placebo group.  Note that this data will need to be verified in Phase 3 trials.

Uncategorized

The American Urological Association (AUA) Best Practice Statement has recently updated its prior recommendation from 2000 now suggesting that urologists start offering patients PSA testing beginning at age 40 years.  This is in contrast with a number of other medical organizations who disagree.

Screening